Cancer immunotherapy has transformed the landscape of oncological treatment by employing various strategies to teach the immune system to eliminate tumors. Among these, cancer nanovaccines are an emerging strategy that utilizes nanotechnology to enhance immune activation in response to tumor antigens. This review addresses the principles behind the different technologies in this field aimed at generating a robust and effective immune response. The diversity of strategies adopted for the design of nanovaccines is discussed, including the types of active agents, nanocarriers, their functionalizations, and the incorporation of adjuvants. Furthermore, strategies to optimize nanoparticle formulations to enhance the antigen presentation, target immune cells, and organs and promote strong and durable antitumor responses are explored. Finally, we analyze the current state of clinical application, highlighting ongoing clinical trials and the future potential of cancer nanovaccines. The insights presented in this review aim to guide future research and development efforts in the field, contributing to the advancement of more effective and targeted nanovaccines in the fight against cancer.
Immunotherapy has transformed the landscape of cancer treatment, driving sustained innovation and investment across the biotechnology sector. Among the most prominent advances, CAR-T cell therapy and cancer nanovaccines have emerged as powerful and potentially complementary strategies with the capacity to reshape clinical practice. Despite their promise, each approach presents distinct strengths and limitations, as demonstrated across preclinical and clinical studies. This review provides a comparative analysis of these platforms, examining their underlying mechanisms, technological features, and recent developments aimed at improving therapeutic efficacy. Particular attention is given to the key challenges that continue to limit their broader clinical translation, including barriers associated with solid tumors, safety, scalability, and the durability of immune responses. We further integrate these discussions into translational clinical decision-making insights intended to support context-dependent patient stratification, therapeutic selection, and rational design of combination immunotherapies. By integrating these perspectives, this work offers an updated overview of CAR-T cell therapies and nanovaccines, emphasizing convergent and divergent features while outlining strategic directions to guide future research and translational development.